Sanara MedTech Confirms OsStic Bio-Adhesive Launch in 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Sanara MedTech, together with Biomimetic Innovations, provided an update on progress related to their strategic alliance. In addition, Sanara reaffirmed its plans to introduce OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. commercial market in the first quarter of 2027, following anticipated clearance by the U.S. Food and Drug Administration, FDA, to support reduction and provisional fixation treatment of the more than 100,000 peri-articular fractures occurring annually nationwide. Seth Yon, Sanara's President and Chief Executive Officer, commented "OsStic exemplifies our commitment to bringing truly innovative solutions to the surgical market. By working closely with BMI, we're expanding our portfolio through our License and Distribution Agreement with BMI to address critical unmet needs in orthopaedic care and strengthen our position as a leader in surgical innovation."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMTI
Wall Street analysts forecast SMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMTI is 36.00 USD with a low forecast of 36.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 21.380
Low
36.00
Averages
36.00
High
36.00
Current: 21.380
Low
36.00
Averages
36.00
High
36.00
About SMTI
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanara MedTech (SMTI) Projects Q4 2025 Revenue of $27.2M to $27.7M
- Revenue Growth Outlook: Sanara MedTech anticipates Q4 2025 net revenue between $27.2 million and $27.7 million, reflecting a year-over-year increase of approximately 3% to 5%, indicating stable growth potential in the market.
- BIASURGE Sales Recovery: The company experienced significant sales growth in its BIASURGE Advanced Surgical Solution due to supply chain issues in Q4 2024, with expected net revenue growth of approximately 11% to 13% year-over-year for Q4 2025.
- Annual Financial Guidance: For the full year 2025, net revenue is projected to range from $102.7 million to $103.2 million, representing a year-over-year increase of about 19%, reflecting ongoing growth in the surgical sector and recovering market demand.
- Future Projections: Sanara MedTech expects full year 2026 net revenue to range from $116 million to $121 million, indicating a growth of approximately 13% to 17% compared to the midpoint of the 2025 revenue forecast, showcasing confidence in future growth.
Continue Reading
Sanara MedTech Secures Innovative Technology Contract with Vizient for BIASURGE
- Innovative Technology Contract: Sanara MedTech's BIASURGE Advanced Surgical Solution has secured a contract with Vizient, effective January 1, 2026, expanding the company's reach within a healthcare network representing over $156 billion in annual purchasing volume.
- Product Advantages: BIASURGE is a no-rinse irrigation solution designed to cleanse surgical wounds more effectively than saline alone, with its antimicrobial preservative providing broad-spectrum effectiveness that supports infection control strategies and enhances surgical precision.
- Market Potential: The contract was awarded based on recommendations from hospital experts, indicating BIASURGE's unique qualities and potential to improve surgical care, which could significantly enhance the company's market competitiveness and sales.
- Portfolio Expansion: Sanara MedTech also markets CellerateRX Surgical Activated Collagen Powder, FORTIFY tissue repair grafts, and advanced biologic matrices, aimed at improving clinical outcomes while reducing healthcare costs, further solidifying its position in the surgical products market.
Continue Reading